BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND ER, estrogen receptor AND Treatment
12573 results:

  • 1. Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors.
    Qi G; Zhang X; Gai X; Yan X
    PeerJ; 2024; 12():e17377. PubMed ID: 38766488
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.
    Yin G; Song G; Xue S; Liu F
    Sci Rep; 2024 May; 14(1):11367. PubMed ID: 38762547
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The impact of loco-regional treatment modality on the outcomes in breast cancer patients younger than forty years of age.
    Boutrus RR; Abdelazim YA; Mohammed T; Bayomy M; Ibraheem MH; Hussein A; Sebaie ME
    BMC Cancer; 2024 May; 24(1):599. PubMed ID: 38760780
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. FGFR2-triggered autophagy and activation of Nrf-2 reduce breast cancer cell response to anti-ER drugs.
    Gorska-Arcisz M; Popeda M; Braun M; Piasecka D; Nowak JI; Kitowska K; Stasilojc G; Okroj M; Romanska HM; Sadej R
    Cell Mol Biol Lett; 2024 May; 29(1):71. PubMed ID: 38745155
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.
    Munter-Young R; Fuentes-Alburo A; DiGregorio N; Neeser K; Gultyaev D
    PLoS One; 2024; 19(5):e0302486. PubMed ID: 38743917
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Neoadjuvant radiotherapy in ER
    Bruss C; Albert V; Seitz S; Blaimer S; Kellner K; Pohl F; Ortmann O; Brockhoff G; Wege AK
    Front Immunol; 2024; 15():1355130. PubMed ID: 38742103
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Regulation of cellular and molecular markers of epithelial-mesenchymal transition by Brazilin in breast cancer cells.
    Cayetano-Salazar L; Hernandez-Moreno JA; Bello-Martinez J; Olea-Flores M; Castañeda-Saucedo E; Ramirez M; Mendoza-Catalán MA; Navarro-Tito N
    PeerJ; 2024; 12():e17360. PubMed ID: 38737746
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The role of clinical breast examination and fine needle aspiration cytology in early detection of breast cancer: A cross-sectional study nested in a cohort in a low-resource setting.
    Mremi A; Pallangyo A; Mshana T; Mashauri O; Kimario W; Nkya G; Mwakyembe TE; Mollel E; Amsi P; Mmbaga BT
    Womens Health (Lond); 2024; 20():17455057241250131. PubMed ID: 38725253
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment.
    Cui Y; Ran R; Da Y; Zhang H; Jiang M; Qi X; Zhang W; Niu L; Zhou Y; Zhou C; Tang X; Wang K; Yan Y; Ren Y; Dong D; Zhou Y; Wang H; Gong J; Hu F; Zhao S; Zhang H; Zhang C; Yang J
    J Cell Mol Med; 2024 May; 28(9):e18374. PubMed ID: 38722288
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice.
    Berg T; Jensen MB; Rossing M; Axelsen CT; Kümler I; Søndergaard L; Vogsen M; Knoop AS; Ejlertsen B
    Acta Oncol; 2024 May; 63():277-287. PubMed ID: 38711384
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
    Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
    Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. H4K20me3, H3K4me2 and H3K9me2 mediate the effect of ER on prognosis in breast cancer.
    Xiao CK; Ren Y; Chen Q; Yang Y; Tang L; Xu L; Ren Z
    Epigenetics; 2024 Dec; 19(1):2343593. PubMed ID: 38643489
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Postpartum breast cancer and Survival in Women With Germline BRCA Pathogenic Variants.
    Zhang Z; Ye S; Bernhardt SM; Nelson HD; Velie EM; Borges VF; Woodward ER; Evans DGR; Schedin PJ
    JAMA Netw Open; 2024 Apr; 7(4):e247421. PubMed ID: 38639936
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Bifunctional HDAC and DNMT inhibitor induces viral mimicry activates the innate immune response in triple-negative breast cancer.
    Fan W; Li W; Li L; Qin M; Mao C; Yuan Z; Wang P; Chu B; Jiang Y
    Eur J Pharm Sci; 2024 Jun; 197():106767. PubMed ID: 38636781
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy.
    Chen H; Gui X; Zhou Z; Su F; Gong C; Li S; Wu W; Rao N; Liu Q; Yao H
    Breast; 2024 Jun; 75():103733. PubMed ID: 38615482
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in breast cancer: A Randomized Clinical Study.
    Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The inositol-requiring enzyme 1 (IRE1) endoplasmic reticulum stress pathway promotes MDA-MB-231 cell survival and renewal in response to the aryl-ureido fatty acid CTU.
    Rahman MK; Umashankar B; Choucair H; Bourget K; Rawling T; Murray M
    Int J Biochem Cell Biol; 2024 Jun; 171():106571. PubMed ID: 38608921
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Active substance and mechanisms of Actinidia chinensis Planch for the treatment of breast cancer was explored based on network pharmacology and in silico study.
    Xu Y; Yang J; Han X; Gan C; Wei X
    Medicine (Baltimore); 2024 Apr; 103(15):e37829. PubMed ID: 38608062
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Significance of estrogen/Progesterone receptor Expression in Metaplastic breast Carcinoma.
    Hashmi AA; Mallick BA; Rashid K; Malik UA; Zia S; Zia F; Irfan M
    Dis Markers; 2024; 2024():2540356. PubMed ID: 38601434
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials.
    Apostolidou K; Zografos E; Papatheodoridi MA; Fiste O; Dimopoulos MA; Zagouri F
    Breast; 2024 Jun; 75():103729. PubMed ID: 38599049
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 629.